HealthRx.com

SURMOUNT-4 Trial: A Plain-English Overview of What It Established

By
Published Updated Last reviewed
GLP-1 medication and metabolic health image for SURMOUNT-4 Trial: A Plain-English Overview of What It Established
Clinical image for SURMOUNT-4 Trial: A Plain-English Overview of What It Established Image: HealthRX.com clinical image

At a glance

| Trial Detail | Value | |---|---| | Trial name | SURMOUNT-4 (NCT04660643) | | Enrolled (N) | 670 randomized (from 783 in lead-in) | | Intervention | Tirzepatide (maximum tolerated dose: 10 mg or 15 mg weekly) | | Comparator | Matching placebo (after 36-week open-label lead-in) | | Total duration | 88 weeks (36-week lead-in + 52-week randomized phase) | | Primary endpoint | Percent change in body weight from randomization (week 36) to week 88 | | Key result | Tirzepatide group lost an additional 5.5%; placebo group regained 14.0% | | Published | 2024, JAMA |

The Question SURMOUNT-4 Was Built to Answer

Every prior obesity drug trial left the same loose thread: if you stop the medication, what happens? Earlier SURMOUNT trials (1 through 3) proved that tirzepatide produces large weight reductions in people with obesity. SURMOUNT-4 addressed the next clinical question directly. It asked whether those weight losses hold up once the drug is withdrawn, or whether continued treatment is necessary to maintain the benefit.

The design was a "randomized withdrawal" trial. Everyone received tirzepatide for 36 weeks first. Only those who tolerated it and lost weight were then randomly assigned to either keep going or switch to placebo. This structure isolated the specific effect of continuation versus discontinuation, removing the noise that comes from comparing people who never responded in the first place.

Who Was in the Trial

Participants were adults aged 18 or older with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related complication (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). People with type 2 diabetes were excluded, keeping the study population consistent with the FDA-approved indication for Zepbound in obesity without diabetes.

Of 783 people who entered the open-label lead-in, 670 (85.6%) met the criteria for randomization at week 36. The most common reasons for not advancing were adverse events and voluntary withdrawal. The randomized group was roughly 70% female, with a mean age of 45 and a mean baseline BMI of 38 kg/m². By randomization, average weight loss during the lead-in was already 20.9%.

How the Trial Worked, Step by Step

Weeks 0 through 36 (open-label lead-in). All 783 participants received tirzepatide, titrated from 2.5 mg weekly up to the maximum tolerated dose of 10 mg or 15 mg. The titration schedule followed the same stepwise protocol used across the SURMOUNT program: 2.5 mg for four weeks, then increases every four weeks. Lifestyle counseling (a 500 kcal/day deficit and 150 minutes/week of physical activity) accompanied the drug throughout.

Week 36 (randomization). Those who had tolerated at least 10 mg weekly and completed the lead-in were randomized 1:1 to continue tirzepatide at their current dose or switch to matching placebo injections. Randomization was stratified by dose level (10 mg vs. 15 mg) and by the presence of prediabetes.

Weeks 36 through 88 (double-blind phase). For 52 weeks, neither participants nor investigators knew who was on drug versus placebo. Lifestyle counseling continued for both groups. Weight, waist circumference, cardiometabolic biomarkers, and adverse events were tracked at regular intervals.

The HealthRX.com Regain-vs-Retention Framework

To make the results concrete, we built a simple before-and-after comparison that tracks what happened to a hypothetical participant who weighed 240 lbs at trial entry.

| Timepoint | Tirzepatide Continuation | Placebo (Switched Off Drug) | |---|---|---| | Week 0 (trial entry) | 240 lbs | 240 lbs | | Week 36 (randomization), after ~20.9% loss | ~190 lbs | ~190 lbs | | Week 88 (trial end) | ~179 lbs (additional 5.5% loss) | ~217 lbs (14.0% regain from week 36) | | Net change from original baseline | ~25.3% total loss | ~9.6% total loss |

The gap between the two groups at week 88 was 19.5 percentage points. Both groups started the randomized period at the same weight. By trial end, the placebo group had regained roughly two-thirds of the weight they initially lost, while the continuation group continued losing. That 19.5-point divergence was statistically significant (p < 0.001) and clinically meaningful by any obesity-medicine standard.

Detailed Results Beyond the Primary Endpoint

Waist circumference. The tirzepatide group lost an additional 4.3 cm from the waist during the randomized phase, while the placebo group gained 7.8 cm. The difference of 12.1 cm matters because waist circumference independently predicts cardiometabolic risk beyond what BMI captures.

Cardiometabolic markers. Systolic blood pressure, fasting insulin, and lipid panels all worsened in the placebo group after withdrawal while remaining stable or improving in the tirzepatide group. These shifts tracked closely with weight changes. Fasting glucose rose in the placebo group, consistent with the known relationship between adiposity rebound and insulin resistance.

Proportion reaching clinically meaningful thresholds. At week 88 to 97.3% of tirzepatide continuers maintained at least 80% of their lead-in weight loss. In the placebo group, that number dropped sharply. Roughly one in three placebo participants regained enough weight to fall below the 5% total-loss threshold that the AMA and Endocrine Society consider clinically significant.

| Outcome at Week 88 | Tirzepatide | Placebo | |---|---|---| | Mean % weight change from randomization | −5.5% | +14.0% | | Maintained ≥5% loss from original baseline | 99.0% | 76.7% | | Maintained ≥10% loss from original baseline | 96.8% | 52.4% | | Maintained ≥20% loss from original baseline | 78.7% | 16.6% | | Waist circumference change (cm) | −4.3 | +7.8 |

Safety During the Randomized Phase

Adverse event rates were consistent with the broader tirzepatide safety profile. Gastrointestinal side effects (nausea, diarrhea, constipation) occurred more often in the tirzepatide group, though rates were lower than during the initial titration phase since participants had already been on stable doses for months.

Serious adverse events were reported in 3.0% of the tirzepatide group and 2.7% of the placebo group. No new safety signals appeared. One finding worth noting: the placebo group experienced a small uptick in musculoskeletal complaints during regain, possibly related to the mechanical stress of rapidly re-accumulating weight.

Discontinuation rates during the double-blind phase were low (roughly 5% in each arm), reflecting the pre-selection of tolerant responders during the lead-in.

Limitations the Authors Acknowledged

The randomized withdrawal design, while excellent for isolating the continuation question, introduces survivorship bias. The 15% of participants who dropped out during the lead-in (due to side effects or non-response) were excluded from the randomized phase. This means the trial's results apply specifically to people who tolerate and respond to tirzepatide, not to the broader population who might start it.

The 52-week randomized phase, while longer than many obesity trials, still leaves open the question of what happens over five or ten years. Weight regain in the placebo group appeared to be plateauing by week 88 in some subgroup analyses, but the trajectory was not fully settled.

The trial population was predominantly White (approximately 85%) and excluded people with type 2 diabetes, limiting generalizability. The SURMOUNT-2 trial covered the diabetes population separately, but a withdrawal study in that group has not been published.

Finally, the lead-in design means there was no true "start placebo from day one" arm. The trial cannot tell us whether a person who never took tirzepatide would have the same weight trajectory as someone who took it and stopped. The comparison is specifically between staying on versus coming off.

What SURMOUNT-4 Means for Clinical Practice

Three practical takeaways emerge from SURMOUNT-4.

First, obesity treatment with tirzepatide (and likely other GLP-1 receptor agonists) appears to require ongoing use. The 14% regain over 52 weeks after stopping is consistent with data from the STEP 1 extension trial with semaglutide, where participants regained roughly two-thirds of lost weight within a year of discontinuation. SURMOUNT-4 confirmed that this pattern is not unique to one molecule. It reflects the biology of obesity rather than a quirk of any single drug.

Second, the speed and magnitude of regain argue against "drug holidays." Some clinicians have considered intermittent dosing to reduce cost or side-effect burden. SURMOUNT-4 provides direct evidence against extended breaks. Weight regain began within weeks of switching to placebo and accumulated steadily.

Third, insurance and access conversations now have harder data. Payers who restrict GLP-1 prescriptions to short courses can no longer argue that the evidence supports limited treatment duration. SURMOUNT-4 demonstrated that stopping treatment reverses most of its benefit, supporting the 2024 AGA clinical practice guideline framing obesity pharmacotherapy as long-term.

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

For More Info Visit HealthRx.com
Visit Now